(VIANEWS) – RANA GRUBER (RANA.OL), BOIRON (BOI.PA), ITERA (ITERA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. RANA GRUBER (RANA.OL)
24.5% sales growth and 68.94% return on equity
Rana Gruber ASA engages in the mining, processing, and sale of iron ore concentrate. The company excavates, processes, and sells iron oxide in the form of hematite, magnetite, and iron oxide pigments. It also produces magnetite iron oxide concentrates. The company offers its products under the Colorana brands. It exports its products worldwide. Rana Gruber ASA was founded in 1937 and is headquartered in Mo i Rana, Norway.
Earnings Per Share
As for profitability, RANA GRUBER has a trailing twelve months EPS of kr7.3.
PE Ratio
RANA GRUBER has a trailing twelve months price to earnings ratio of 8.22. Meaning, the purchaser of the share is investing kr8.22 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 68.94%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 573.6% and a drop 29.5% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
RANA GRUBER’s EBITDA is 4.35.
Sales Growth
RANA GRUBER’s sales growth for the next quarter is 24.5%.
Yearly Top and Bottom Value
RANA GRUBER’s stock is valued at kr60.00 at 17:20 EST, under its 52-week high of kr65.00 and way higher than its 52-week low of kr37.05.
More news about RANA GRUBER.
2. BOIRON (BOI.PA)
17.3% sales growth and 8.13% return on equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.89.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 13.43. Meaning, the purchaser of the share is investing €13.43 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.
More news about BOIRON.
3. ITERA (ITERA.OL)
11.2% sales growth and 138.07% return on equity
Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, ITERA has a trailing twelve months EPS of kr0.59.
PE Ratio
ITERA has a trailing twelve months price to earnings ratio of 22.03. Meaning, the purchaser of the share is investing kr22.03 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 138.07%.
More news about ITERA.
4. MEDISTIM (MEDI.OL)
10.2% sales growth and 33.83% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr3.84.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 73.42. Meaning, the purchaser of the share is investing kr73.42 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.83%.
Sales Growth
MEDISTIM’s sales growth is 26% for the ongoing quarter and 10.2% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.6%, now sitting on 491.94M for the twelve trailing months.
Yearly Top and Bottom Value
MEDISTIM’s stock is valued at kr282.00 at 17:20 EST, way below its 52-week high of kr330.00 and way above its 52-week low of kr184.80.
More news about MEDISTIM.
